# Interest of Anti-telomerase T CD4 Immune Responses for Predicting the Effectiveness of Immunotherapies Targeting PD1 / PDL1

> **NCT02840058** · NA · COMPLETED · sponsor: **Centre Hospitalier Universitaire de Besancon** · enrollment: 295 (actual)

## Conditions studied

- Cancer

## Interventions

- **OTHER:** Biological samples
- **DRUG:** Anti PD1/PDL1 treatment

## Key facts

- **NCT ID:** NCT02840058
- **Lead sponsor:** Centre Hospitalier Universitaire de Besancon
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08-31
- **Primary completion:** 2024-07-23
- **Final completion:** 2025-07-15
- **Target enrollment:** 295 (ACTUAL)
- **Last updated:** 2026-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02840058

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02840058, "Interest of Anti-telomerase T CD4 Immune Responses for Predicting the Effectiveness of Immunotherapies Targeting PD1 / PDL1". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT02840058. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*